Growth hormone treatment in pediatric burns: a safe therapeutic approach.

Ramirez RJ, Wolf SE, Barrow RE, Herndon DN

Annals of surgery1 Oct 1998Cited by 67 (Europe PMC)

PMID9790334DOI10.1097/00000658-199810000-00001PepBankPUB-09790334

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialSafety outcome
In severely burned children, mortality was 2% with rhGH and saline placebo in controlled studies.
In plain wordsIn severely burned children, mortality was 2% with rhGH and saline placebo in controlled studies.
Peptide
HGH (somatotropin)
Outcome
No significant changeMortality in controlled studies
Study
n: not reported in source
Comparator
Saline placebo
Outcome group
Mortality · Whole body
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Measurements
Mortality
2%
rhGH group, controlled studies
Mortality
2%
saline placebo group, controlled studies
Source sentences
Summary
A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033401
02HumanRandomized controlled trialSafety outcome
In severely burned children, rhGH did not differ from saline placebo in septic complications in controlled studies.
In plain wordsIn severely burned children, septic complications did not differ between rhGH and saline placebo in controlled studies.
Peptide
HGH (somatotropin)
Outcome
No significant changeSeptic complications
Study
n: not reported in source
Comparator
Saline placebo
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033402
03HumanRandomized controlled trialSafety outcome
In severely burned children, organ dysfunction did not differ between rhGH and saline placebo in controlled studies.
In plain wordsIn severely burned children, organ dysfunction did not differ between rhGH and saline placebo in controlled studies.
Peptide
HGH (somatotropin)
Outcome
No significant changeOrgan dysfunction
Study
n: not reported in source
Comparator
Saline placebo
Outcome group
Adverse events · Whole body
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033403
04HumanRandomized controlled trialSafety outcome
In severely burned children, heart rate pressure product did not differ between rhGH and saline placebo in controlled studies.
In plain wordsIn severely burned children, heart rate pressure product did not differ between rhGH and saline placebo in controlled studies.
Peptide
HGH (somatotropin)
Outcome
No significant changeHeart rate pressure product
Study
n: not reported in source
Comparator
Saline placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033404
05HumanObservational studySafety outcome
In severely burned children, mortality did not differ between therapeutic rhGH recipients and their controls.
In plain wordsIn severely burned children, mortality did not differ between therapeutic rhGH recipients and their controls.
Peptide
HGH (somatotropin)
Outcome
No significant changeMortality with therapeutic rhGH
Study
n: not reported in source
Comparator
Controls
Outcome group
Mortality · Whole body
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
In addition, no difference in mortality could be shown for those given rhGH therapeutically versus their controls.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033405
06HumanObservational studySafety outcome
In severely burned children, blinded autopsy review attributed no patient deaths to rhGH.
In plain wordsIn severely burned children, blinded autopsy review attributed no deaths to rhGH.
Peptide
HGH (somatotropin)
Outcome
Not applicableDeaths attributed to rhGH
Study
n: not reported in source
Outcome group
Mortality · Whole body
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
No patient deaths were attributed to rhGH in autopsies reviewed by observers blinded to treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033406
07HumanObservational studySafety outcome
In severely burned children, hyperglycemic episodes were higher among rhGH recipients.
In plain wordsIn severely burned children, high blood sugar episodes were more frequent among rhGH recipients.
Peptide
HGH (somatotropin)
Outcome
IncreaseHyperglycemic episodes
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033407
08HumanObservational studySafety outcome
In severely burned children, exogenous insulin requirements were higher among rhGH recipients.
In plain wordsIn severely burned children, insulin requirements were higher among rhGH recipients.
Peptide
HGH (somatotropin)
Outcome
IncreaseExogenous insulin requirements
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033408
09HumanObservational studyEfficacy outcome
In severely burned children, exogenous albumin requirements were reduced among rhGH recipients.
In plain wordsIn severely burned children, albumin requirements were lower among rhGH recipients.
Peptide
HGH (somatotropin)
Outcome
DecreaseExogenous albumin requirements
Study
n: not reported in source
Outcome group
Supportive Care Requirements · Whole body
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033409
10HumanObservational studySafety outcome
In severely burned children, hypocalcemia development was reduced among rhGH recipients.
In plain wordsIn severely burned children, low blood calcium developed less often among rhGH recipients.
Peptide
HGH (somatotropin)
Outcome
DecreaseHypocalcemia
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced.
2 context sentences(design, population, supporting numbers)
Summary · context
The records of 263 children who were burned were reviewed.
Summary · context
Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82)
Report a problemFND-0979033410

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.